EP1529526A1 — Sustained-release pharmaceutical compositon

USPTO Abstract

As compared with the current oral sustained-release preparation containing tamsulosin hydrochloride which have been supplied to the medical setting at present, it is needed to provide a sustained-release pharmaceutical composition in which the efficacy is equivalent or even better, adverse events such as adverse reactions (e.g., postural hypotension) are reduced, dose can be increased and, if desired, ingestion of food is not limited in the dosage and it is also needed to provide a method for administration of tamsulosin hydrochloride in which the adverse reactions accompanied by therapy or prevention on the basis of an α 1 receptor blocking action are reduced. A sustained-release pharmaceutical composition, characterized in that, there are contained tamsulosin or a pharmaceutically acceptable salt thereof and a carrier for a sustained-release pharmaceutical composition and the ratio (C min /C max ratio) of the plasma tamsulosin concentration at 24 hours after the administration of the preparation per os (C min ) to the maximum plasma tamsulosin concentration after the administration (C max ) is about 0.4 or more.